Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 12 Years and Older

Similar documents
Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older

APPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe

Drug Class Monograph

Inhaled Corticosteroid Dose Comparison in Asthma

Diagnosis and Management of Asthma

Inhaled Corticosteroids Drug Class Prior Authorization Protocol

Inhaled Corticosteroids Drug Class Prior Authorization Protocol

See Important Reminder at the end of this policy for important regulatory and legal information.

Alberta Childhood Asthma Pathway for Primary Care

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder

Aerospan (flunisolide)

Orally Inhaled Corticosteroids to 2022

A Visual Approach to Simplifying Respiratory Drug Regimens

benralizumab (Fasenra )

The Medical Letter. on Drugs and Therapeutics

Clinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:

COPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy

reslizumab (Cinqair )

Improving Outcomes in COPD

BREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate)

BREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate)

BREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate)

Select Inhaled Respiratory Agents

COPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes

Nucala (mepolizumab injection for subcutaneous use)

MDI Bonanza. Dwayne Griffin, DO

CLINICAL MEDICAL POLICY

1.* Dosage. A. Adults

A Visual Approach to Simplifying Respiratory Drug Regimens

Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS

A Visual Approach to Simplifying Respiratory Drug Regimens

Key features and changes to these four components of asthma care include:

Long Term Care Formulary RS -29

See Important Reminder at the end of this policy for important regulatory and legal information.

Cinqair (reslizumab injection for intravenous use)

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

COPD Medicine. No one ever showed me how to use this. Wendy Happel; RRT, COPD Educator Krystal Fedoris; RRT-NPS, BA, COPD Educator

What You Need to Know about Metered-Dose Inhalers and the HFA Propellant

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

MANAGING ASTHMA. Nancy Davis, RRT, AE-C

Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath.

SAMPLE. mg by mouth every day for day(s) Prednisolone. Other Medicine: Medicine Dose How long Directions

Disclosure. Case. Objectives. Case Continued. Inhalers. Asthma: A GINA Update to the NAEPP 2007 Guidelines 1/20/2015

See Important Reminder at the end of this policy for important regulatory and legal information.

AIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol

Stepping down asthma treatment guidelines

Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless?

Clinical Policy: Mepolizumab (Nucala) Reference Number: ERX.SPA.214 Effective Date:

Question I was one of the first dry power devices available in the US Flovent, Serevent and Advair are all available in this device

Asthma. Definition. Symptoms

Allergies and Asthma 5/21/2013. Objectives. Allergic Rhinitis (AR): Risk Factor for ASTHMA. Rhinitis and Asthma

Clinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:

Clinical Policy: Omalizumab (Xolair) Reference Number: ERX.SPA.141 Effective Date: Last Review Date: 08.17

Preschool Asthma What you need to know in 10 minutes

US max daily dose i Food and Drug Administration [2]

See Important Reminder at the end of this policy for important regulatory and legal information.

Reference Guide for Caring for Pediatric Patients with Asthma

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

Drug Effectiveness Review Project Summary Report

Stakeholder Comments and Ontario Drug Policy Research Network (ODPRN) Response:

Correct Use of Inhaler Devices

ANTINEOPLASTIC DRUGS CHAPTER 21. Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component

Breakout Session # A 12:45 1:25. New Methods of Medication Delivery to the Lungs: Say Goodbye to the MDI as we know it

STRIVERDI RESPIMAT (olodaterol hcl) aerosol

GMMMG Asthma Formulary Inhaler Options August 2017

First to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida

How to Use Inhaled Medications for Asthma and COPD

Asthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options

The Inflammatory Response. Inflammation in the Airway. The Inflammatory Response. Inflammation in the Airway. Inflammation in the Airway

Supplementary materials

DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL

Dose. Route. Units. Given. Dose. Route. Units. Given

Medications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources

THE COPD PRESCRIBING TOOL

Respiratory Health. Asthma and COPD

See Important Reminder at the end of this policy for important regulatory and legal information.

Enhancing Patient Care

Improving Outcomes in COPD. Improving Outcomes in COPD 4/4/2018

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical

Adult Emergency Department Asthma Care Pathway (EDACP)

See Important Reminder at the end of this policy for important regulatory and legal information.

Asthma/COPD Update with Inhaler Workshop

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health

ASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12

Respiratory Inhalers. Identification Guide Version 3

Common Inhaled Asthma Medications Dose Comparison and Tips for Use

GINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017

Effective Date: 4/27/2016 Version: 1.0 Approval By: CCC Clinical Delivery Steering Planned Review Date: 4/27/2017

How to Use Inhaled Medications

Stepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs

Nancy Davis, RRT, AE-C

Rapporteur s Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended

QUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)

AT TRIAGE. Alberta Acute Childhood Asthma Pathway: Evidence based* recommendations For Emergency / Urgent Care

CAMPER APPLICATION PACKET

2014 Step Therapy Criteria (List of Step Therapy Criteria)

Respiratory Medications and Devices Update 2/15

Pediatric Asthma: Pharmacotherapy. Joseph Spahn, MD Children s Hospital Colorado & University of Colorado Medical School Aurora, Colorado

INHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop

FASENRA (benralizumab)

Transcription:

Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 12 Years and Older The Canadian Thacic Society recommends a tempary, greater the inhaled cticosteroid () dose in selected patients in response to wsening asthma symptoms. 1 The green yellow red zone framewk describes asthma symptoms that are controlled, partially controlled uncontrolled, respectively. This guideline based recommendation is distinct from the manufacturer s recommended dose in the product monograph. Any the dose requires an individual assessment by the clinician a written asthma action plan. F all examples in this document, the tempary dose does not exceed the manufacturer s recommended maximum dose. As a result, it is not possible to recommend an evidenced based greater the all dosage situations. In the absence of an evidence based option, clinicians exercising clinical judgment may choose a 2 fold the dose. Initiating prednisone in the yellow zone is also an alternative evidence based option. Dose Dose of dose in Fluticasone propionate pmdi Flovent HFA 50 /puff 2 puff ** 125 /puff 1 puff * 250 500 0 125 /puff 500 8 puffs *** 0 0 250 /puff 1 puff * 500 0 0 250 /puff 0 0 0 *Although the manufacturer recommends that the usual dose be obtained using 2 puffs from each available strength of Flovent HFA pmdi, one puff multiple puffs may be required to obtain the prescribed dose. **Increasing the dose beyond may be impractical, an frequency to qid dosing may be considered. ***Switching from the 125 to the 250 pmdi will reduce the number of puffs required per dose. Dose Dose of dose in Fluticasone propionate Flovent Diskus /inhalation 1 inh 4 inhalations 250 /inhalation 1 inh 500 4 inhalations 0 0 500 /inhalation 1 inh 0 2 inhalations 0 0 Dose based on 1 inhalation from each available strength of Flovent Diskus. Me than 1 inhalation may be required to obtain the prescribed dose from the patient s inhaler Dose Dose of dose in Fluticasone furoate* Arnuity Ellipta /inhalation 1 inh 2 inhalations /inhalation 1 inh No recommendation** *Dose based on 1 inhalation from each available strength of Arnuity Ellipta. Me than 1 inhalation may be required to obtain the prescribed dose from the lower strength inhaler.. 1

Budesonide Pulmict Turbuhaler /inhalation 1 inh /inhalation 1 inh /inhalation 1 inh Dose 4 inhalations 4 inhalations 3 inhalations Total dose 1 dose In 1600 2 Dose based on 1 inhalation from each available strength of Pulmict Turbuhaler. Me than 1 inhalation may be required to obtain the prescribed dose from the patient s inhaler. Beclomethasone pmdi Qvar 50 /puff 1 puff 50 /puff /puff 1 puff /puff Dose 8 puffs Total dose dose In Dose based on 1 puff from each available strength of Qvar inhaler. Me than 1 inhalation may be required to obtain the prescribed dose from the patient s inhaler. Ciclesonide pmdi Alvesco /puff 1 puff * /puff 2 puffs /puff 1 puff /puff 2 puffs /puff Dose using the patient s existing inhaler Total dose dose In *Dose based on 1 puff from each available strength of Alvesco inhaler. Me than 1 inhalation may be required to obtain the prescribed dose from the patient s inhaler. Medication in the Green Zone Dose using the patient s existing inhaler Total dose dose Mometasone Asmanex Twisthaler /inhalation 1 inh 4 inhalations /inhalation 1 inh * 2 inhalations /inhalation 1 inh 2 inhalations /inhalation 1 inh 1 inhalation /inhalation 1 inh *Dose based on 1 puff from each available strength of Asmanex Twisthaler. Me than 1 inhalation may be required to obtain the prescribed dose from the patient s inhaler. 2

Advair pmdi Fluticasone/salmeterol* 125/25 500 Dose using additional fluticasone pmdi, Flovent HFA switching to the higher strength of Advair pmdi Add fluticasone 250 /puff pmdi 3 puffs Switch to Advair 250/25 dose In 0 0 250/25 0 Add fluticasone 250 /puff pmdi 0 *Note: Since each puff from the Advair pmdi delivers salmeterol 25, the manufacturer s recommended dose is 2 puffs from each available strength of Advair pmdi in der to obtain 50 of salmeterol at each dose time. Advair Diskus Fluticasone/salmeterol* /50 1 inhalation Dose using additional doses from the fluticasone, Flovent Diskus switch to a higher strength of Advair Diskus combine the 2 strategies Add fluticasone 250 /inhalation, 1 inhalation add fluticasone /inhalation, 3 inhalations 700 0 3.5 fold 5 fold 250/50 1 inhalation 500 Add fluticasone 250 /inhalation, 3 inhalations add fluticasone 500 /inhalation, 1 inhalation plus fluticasone 500, 1 inhalation 0 1500 0 0 500/50 1 inhalation 0 Add fluticasone 500 /inhalation, 1 inhalation 0 *Note: Since each inhalation from the Advair Diskus delivers salmeterol 50, the manufacturer s recommended dose is 1 inhalations from each available strength of Advair Diskus in der to obtain 50 of salmeterol at each dose time. 3

Breo Ellipta Fluticasone furoate/vilanterol* /25 1 inhalation Dose using additional doses from the fluticasone furoate, Arnuity Ellipta switch to a higher strength of Breo Elliipta Add fluticasone furoate /inh, 1 inhalation Switch to Breo Ellipta /25, 1 inhalation /25 1 inhalation *Note: Each inhalation from either strength of Breo Ellipta delivers vilanterol 25, which is the maximum dose Note: Breo Ellipta /25 and /25 are indicated in asthma. Breo Ellipta /25 is not indicted f use in COPD. Zenhale pmdi Mometasone/fmoterol* Dose using Additional mometasone, Asmanex Twisthaler switch to a higher strength of Zenhale pmdi /5 Add mometasone /inhalation 1 inhalation Switch to Zenhale /5 /5 *Note: Since each puff from the Zenhale pmdi delivers fmoterol 5, the manufacturer s recommended dose is 2 puffs from each available strength of Zenhale pmdi in der to obtain 10 of fmoterol at each dose time. Note: The addition of mometasone, Asmanex Twisthaler as a strategy to increase the inhaled cticosteroid dose introduces a different device (breath actuated, dry powder inhaler) and may necessitate patient education on the use of the new device. 4

Symbict Turbuhaler Budesonide/fmoterol* /6 1 inhalation /6 1 inhalation /6 2 inhalations /6 2 inhalations Dose using Existing Symbict Turbuhaler Symbict Adjustable Maintenance Dosing Increase to 4 inhalations/day dose /6 1 inhalation /6 1 inhalation /6 2 inhalations /6 2 inhalations Increase to 4 inhalations/day alone, add budesonide 1 inhalation Or continue 2 inh + budesonide 2 inh 1600 1600 1600 2 2 /6 1 2 inhalations 2 inhalations /6 1 2 inhalations 2 inhalations to to Symbict Maintenance and Reliever Therapy (SMART) In addition to the dose, may take 1 additional dose as needed in response to symptoms. Not me than 6 inhalations on any single occasion. Not me than 8 inhalations per day in total ( and reliever doses).** Up to /day Up to 1600 /day Up to Up to *Dose based on 1 inhalation from each available strength of Symbict Turbuhaler. Not me than 6 inhalations should be taken on any single occasion **If satisfacty relief of asthma symptoms is not achieved with a maximum of 8 inhalations per day, seek medical attention. Reference: 1. Lougheed MD, Lemière C, Ducharme FM, et al. Canadian Thacic Society 2012 guideline update: Diagnosis and management of asthma in preschoolers, children and adults. Can Resp J 2012;19(2):127 164. Copyright This document is provided f clinicians, as resource in the management of asthma f persons aged 12 years and older. Determination of the most appropriate dose of inhaled cticosteroid f any individual is the responsibility of the clinician together with the patient. The Ontario Lung Association makes no claims about the appropriateness of the inhaled cticosteroid dose. 5